Search This Blog

Thursday, February 2, 2023

Biophytis: Positive Phase 2-3 COVA Study with Sarconeos (BIO101) in Severe COVID-19

 

  • COVA study met primary end point with 44% significant reduction in the risk of respiratory failure or early death

  • Filing for Early Access Programs to Sarconeos (BIO101) is being initated while preparing for Marketing Authorisation in Europe and the USA

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)